Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus

被引:7
|
作者
Bayomy, Omar [1 ]
Rao, Ajay D. [1 ,2 ,3 ,4 ]
Garg, Rajesh [1 ,2 ]
Vaidya, Anand [1 ,2 ]
Kotin, Alyssa R. [2 ]
Reiber, Beata [5 ]
Nijmeijer, Stephanie [5 ]
Di Carli, Marcelo F. [1 ,5 ,6 ]
Jerosch-Herold, Michael [1 ,5 ]
Kwong, Raymond Y. [1 ,6 ]
Adler, Gail K. [1 ,2 ]
机构
[1] Harvard Med Sch, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA
[3] Lewis Katz Sch Med, Sect Endocrinol Diabet & Metab, Philadelphia, PA USA
[4] Lewis Katz Sch Med, Ctr Metab Dis Res, Philadelphia, PA USA
[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
type; 2; diabetes; plasminogen activator inhibitor-1; pericardial fat; adipose tissue; EPICARDIAL ADIPOSE-TISSUE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTORS; PAI-1; ASSOCIATION; HEART; DYSFUNCTION; EXPRESSION; PREVENTION;
D O I
10.1089/met.2017.0031
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Plasminogen activator inhibitor-1 (PAI-1) is implicated in the pathophysiology of cardiovascular disease (CVD) and increased in individuals with type 2 diabetes mellitus (T2DM). Adipose tissue produces PAI-1, and pericardial fat is a CVD risk factor. We sought to determine the relationship between PAI-1 and pericardial fat in males and females with well-controlled T2DM. Methods: The study population consisted of 32 males and 19 females, aged 35-70 years with T2DM, without clinical evidence of CVD or other active medical problems except for hypertension. Subjects were studied under good cardiometabolic control. Study procedures included fasting blood work and cardiovascular imaging. Cardiac magnetic resonance imaging of the heart was used to identify and quantify pericardial fat from the bifurcation of the pulmonary trunk to the last slice containing cardiac tissue. Results: PAI-1 was positively correlated with pericardial fat (beta = 0.72, r = 0.72, P < 0.001) as well as with homeostatic model assessment of insulin resistance (r = 0.31, P = 0.03) and serum triglycerides (r = 0.27, P = 0.05). In a multivariable regression model, controlling for insulin sensitivity, triglycerides, and body mass index, pericardial fat was independently associated with PAI-1 (beta = 0.80, P < 0.001). Conclusions: PAI-1 is positively associated with pericardial fat in individuals with T2DM.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [1] Impact of Ethnicity on the Association of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms with Type 2 Diabetes Mellitus
    Al-Hamodi, Z.
    Saif-Ali, R.
    Ismail, I. S.
    Poh, R.
    Ahmed, R. H.
    Muniandy, S.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 30 - 30
  • [2] Association of fibrinogen and plasminogen activator inhibitor-1 with diabetes mellitus
    Aziz, Iffat Ara
    Fawwad, Asher
    Siddiqui, Iftikhar Ahmed
    Perveen, Kahkashan
    Nangrejo, Ruqaya
    Waris, Nazish
    Basit, Abdul
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 35 (01) : 165 - 169
  • [3] Simvastatin reduces plasma levels of plasminogen activator inhibitor-1 in patients with type 2 diabetes mellitus
    Dharmalingam, S
    Ludwig, S
    Ren, S
    Fenton, JW
    Velthuis, HTE
    Shen, G
    DIABETES, 2001, 50 : A457 - A457
  • [4] Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus'' by Bayomy et al. (Metab Syndr Relat Disord 2017;15:269-275)
    Avogaro, Angelo
    METABOLIC SYNDROME AND RELATED DISORDERS, 2017, 15 (06) : 266 - 268
  • [5] Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease
    Lyon, CJ
    Hsueh, WA
    AMERICAN JOURNAL OF MEDICINE, 2003, 115 : 62 - 68
  • [6] Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity
    Umpaichitra, V
    Hussain, MM
    Castells, S
    PEDIATRIC RESEARCH, 2005, 58 (03) : 483 - 487
  • [7] Plasminogen Activator Inhibitor-1 and Tissue-Plasminogen Activator in Minority Adolescents with Type 2 Diabetes and Obesity
    Vatcharapan Umpaichitra
    M Mahmood Hussain
    Salvador Castells
    Pediatric Research, 2005, 58 : 483 - 487
  • [8] Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus
    Silvija Canecki-Varžić
    Ivana Prpić-Križevac
    Ines Bilić-Ćurčić
    BMC Endocrine Disorders, 16
  • [9] Plasminogen activator inhibitor-1 gene polymorphism as a risk factor for vascular complications in type 2 diabetes mellitus
    Khalaf, Fatma A.
    Ibrahim, Hatem R.
    Bedair, Hanan M.
    Allam, Maha M.
    Elshormilisy, Amr A.
    Ali, Samia T.
    Gaber, Waseem M.
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2019, 20 (01)
  • [10] Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study
    Davidson, M.
    Zhu, J.
    Lu, W.
    Tracy, R. P.
    Robbins, D. C.
    Resnick, H. E.
    Ruotolo, G.
    Howard, B. V.
    DIABETIC MEDICINE, 2006, 23 (10) : 1158 - 1159